Recombinant Humanized Anti-CD25 Monoclonal Antibody
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Recombinant Humanized Anti-CD25 Monoclonal Antibody, covering 2024-10-28 to 2024-10-28. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia [Phase 2]